Roche’s lampalizumab generates cautious Phase III optimism for GA associated dry AMD, major uptake hurdle - experts

27 Oct 2016

Roche’s (VTX:ROG) lampalizumab has generated guarded optimism for its Phase III chances, and while hailed as a potential breakthrough for geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), experts agreed uptake obstacles will block its success.

While physicians are excited for a treatment option, and analysts also forecast this as a blockbuster, market concerns surround patient adherence and the need for biomarker testing, experts added.

Lampalizumab is currently in two Phase III trials, CHROMA (NCT02247479) and SPECTRI (NCT02247531), in 936 patients with GA secondary to dry AMD -- expected to read out in 2017.

Lampalizumab is a monoclonal antibody that binds to complement factor D (CFD), a rate-limiting enzyme involved in the activation of the alternative complement pathway (ACP), a component of the immune system.

Already a subscriber? Login to read the full article.